摘要
目的探讨奥希替尼、培美曲塞、贝伐单抗三联化疗对表皮生长因子受体(EGFR)突变型非小细胞肺癌(NSCLC)的疗效及安全性。方法对2016年7月至2018年12月威海市中心医院收治并确诊的106例EGFR突变型NSCLC患者临床资料进行回顾性分析,根据资料中患者的治疗方法不同纳入对照组和观察组,各53例。对照组男31例、女22例,年龄(60.37±3.54)岁,给予培美曲塞和贝伐单抗治疗。观察组男26例、女27例,年龄(60.82±3.57)岁,给予奥希替尼、培美曲塞、贝伐单抗联合治疗。比较两组患者化疗疗效、血清肿瘤标志物、不良反应以及预后生存情况。计量资料采用独立样本t检验及配对t检验,计数资料采用χ^(2)检验。结果治疗后,观察组治疗总有效率和疾病控制率分别为81.13%(43/53)、92.45%(49/53),均明显高于对照组60.38%(32/53)、77.36%(41/53),差异均有统计学意义(χ^(2)=5.517、4.711,P=0.019、0.030)。治疗前,两组患者癌抗原125(CA125)、角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)水平比较,差异均无统计学意义(均P>0.05);治疗后,观察组CA125、CYFRA21-1、CEA水平分别为(38.69±4.69)U/ml、(2.51±0.52)μg/L、(17.69±3.19)μg/L,均低于对照组(54.23±5.36)U/ml、(4.91±0.73)μg/L、(26.73±5.34)μg/L,差异均有统计学意义(均P<0.05)。两组患者的不良反应发生率比较,差异无统计学意义(χ^(2)=1.485,P=0.223)。对照组患者的3年生存率为52.83%(28/53),明显低于观察组73.58%(39/53),差异有统计学意义(χ^(2)=5.972,P=0.015)。结论奥希替尼、培美曲塞、贝伐单抗三联化疗对EGFR突变型NSCLC患者的治疗效果好,且不会增加不良反应,同时能够改善患者预后。
Objective To investigate the efficacy and safety of triple chemotherapy with osimertinib,pemetrexed,and bevacizumab in epidermal growth factor receptor(EGFR)mutant non-small cell lung cancer(NSCLC).Methods The clinical data of 106 patients with EGFR-mutant NSCLC who were diagnosed in Weihai Central Hospital from July 2016 to December 2018 were retrospectively analyzed.The cases in the control group[53 cases,31 males and 22 females,aged(60.37±3.54)years]were given pemetrexed and bevacizumab,and the cases in the observation group[53 cases,26 males and 27 females,aged(60.82±3.57)years]were given the combined treatment of osimertinib,pemetrexed,and bevacizumab.The chemotherapy efficacy,serum tumor markers,adverse reactions,and survival rate were compared between the two groups.Independent sample t test and paired t test were used for the measurement data,andχ^(2) test was used for the count data.Results After treatment,the total effective rate and disease control rate in the observation group were 81.13%(43/53)and 92.45%(49/53),respectively,which were significantly higher than those in the control group[60.38%(32/53)and 77.36%(41/53)],with statistically significant differences(χ^(2)=5.517,4.711;P=0.019,0.030).Before treatment,there were no statistically significant differences in the levels of cancer antigen 125(CA125),keratin 19 fragments(CYFRA21-1),and carcino-embryonic antigen(CEA)between the two groups(all P>0.05);after treatment,the levels of CA125,CYFRA21-1,and CEA in the observation group were(38.69±4.69)U/ml,(2.51±0.52)μg/L,and(17.69±3.19)μg/L,respectively,which were significantly lower than those in the control group[(54.23±5.36)U/ml,(4.91±0.73)μg/L,and(26.73±5.34)μg/L],with statistically significant differences(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(χ^(2)=1.485,P=0.223).The 3-year survival rate of the control group was 52.83%(28/53),which was significantly lower than that of the observation group[73.58%(39/53)
作者
慈明伟
刘楠
高璐璐
Ci Mingwei;Liu Nan;Gao Lulu(Department of Oncology,Weihai Central Hospital,Weihai 264400,China;Department of Thoracic Surgery,Weihai Central Hospital,Weihai 264400,China)
出处
《国际医药卫生导报》
2022年第10期1418-1421,共4页
International Medicine and Health Guidance News
